ArticleCase reports in hematology2026
Unmasking Evans Syndrome: A Case of New Onset Anemia and Thrombocytopenia in a Pregnant Patient With Systemic Lupus Erythematosus.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unmasking Evans Syndrome: A Case of New Onset Anemia and Thrombocytopenia in a Pregnant Patient With Systemic Lupus Erythematosus.Case reports in hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evans Syndrome (ES) is an immune-mediated disorder defined by the presence of two or more autoimmune cytopenias, typically autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP), with or without associated neutropenia. The disease can be classified as primary (i.e., idiopathic) or secondary to other underlying conditions, such as systemic lupus erythematosus (SLE), lymphoproliferative disorders, infections, and immunodeficiency states. We present a case of ES in a 21-year-old pregnant woman (G1P0, 19 weeks and 2 days gestation) secondary to SLE. The patient was treated with high-dose steroids and intravenous immunoglobulin therapy (IVIG), resulting in marked improvement in her cell counts. Following delivery, she was diagnosed with SLE and began treatment with rituximab and hydroxychloroquine, leading to remission of her symptoms and normalization of her anemia and thrombocytopenia. The varied presentations and associated conditions make ES a challenging diagnostic conundrum. Differentiating between primary and secondary ES is crucial for prognosis and management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.